Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/psyg.12215 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Valproate-induced hyperammonemic encephalopathy in neurosurgical patients: Our experience and systematic literature review.
Neurosurg Rev
November 2024
Department of Neurosurgery, Neurosciences Centre, All India Institute of Medical Sciences, New Delhi, India.
Article Synopsis
- Sodium valproate is commonly used to treat seizures, chronic pain, and bipolar disorder, but it can cause severe side effects like valproate-induced hyperammonemic encephalopathy (VHE), which is life-threatening.
- A study reviewed four neurosurgical patients who developed VHE after using valproate for seizure prevention, revealing a 50% mortality rate and indicating that prompt diagnosis and treatment are crucial.
- Treatment involved discontinuing valproate and, in some cases, dialysis; half of the patients experienced clinical improvement after normalization of ammonia levels.
A microRNA signature for valproate-induced steatosis in human hepatocytes and its application to predict fatty liver in paediatric epileptic patients on valproate therapy.
Toxicology
December 2024
Department Biochemistry & Molecular Biology, University of Valencia, Spain; Experimental Hepatology Joint Research Unit. IIS Hospital La Fe. Valencia, Spain; CIBERehd, ISCIII, Madrid, Spain. Electronic address:
Article Synopsis
- - Valproate (VPA), commonly prescribed for epilepsy in children, can lead to liver issues like hepatic steatosis, but many cases may go unnoticed due to a lack of specific biomarkers.
- - The study aimed to demonstrate that VPA causes triglyceride accumulation in liver cells and to identify microRNAs (miRNAs) linked to this effect as potential non-invasive biomarkers for liver steatosis in children.
- - The researchers found that certain miRNAs were significantly altered in children taking VPA, and this signature identified 18 patients at risk for liver steatosis, highlighting a connection between high VPA levels, younger age, and liver enzyme changes.
Sodium Valproate-Induced Hyperammonemia: A Case Series in a Tertiary Care Hospital.
Cureus
July 2024
Pharmacology, Christian Medical College and Hospital, Ludhiana, IND.
Background: Sodium valproate (VPA) is an extensively used anti-convulsant, which is an effective drug for treatment of epilepsy in adults and children, as well as for conditions like migraine, bipolar disorder, mania, and trigeminal neuralgia. Sedation, vertigo, ataxia, dose-dependent tremors, headaches, and gastrointestinal side effects are the most often reported adverse effects associated with VPA. A potential life-threatening event reported with VPA is hyperammonemia (HA), which is defined as an increase in serum level of ammonia.
View Article and Find Full Text PDFAssociation of UGT1A6 gene polymorphisms with sodium valproate-induced tremor in patients with epilepsy.
Seizure
August 2024
Department of Neurology, Qinghai Provincial People's Hospital, Xining, China. Electronic address:
Article Synopsis
- The study investigates how genetic variations in the UGT1A6 gene may influence individual responses to sodium valproate (VPA), particularly in causing tremors in epilepsy patients.
- A total of 128 patients were analyzed, and those with the UGT1A6 A541G mutant genotype showed a significant association with increased risk of tremors compared to those with the wild-type genotype.
- Early identification of the A541G mutant could lead to more personalized VPA treatment plans to minimize adverse effects for patients with epilepsy.
Valproate-induced disabling tremor in a case of Rasmussen's encephalitis.
Indian J Pharmacol
January 2024
Department of Neurology, King George's Medical University, Lucknow, Uttar Pradesh, India.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!